Study of XL999 in Patients With Previously Treated Ovarian Cancer

Inclusion Criteria: * Female patients with a histologically confirmed diagnosis of metastatic ovarian cancer * Measurable disease according to Response Criteria for Solid Tumors (RECIST) * Prior treatment with platinum-based therapy * Platinum-sensitive or platinum-resistant disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of ≥3 months * Adequate organ and marrow function * Signed informed consent * No other malignancies within 5 years Exclusion Criteria: * Radiation to ≥25% of bone marrow within 30 days of XL999 treatment * Use of an investigational drug or cytotoxic chemotherapy within 30 days of XL999 treatment * Prior anticancer therapy targeting VEGF (eg, bevacizumab, sorafenib, or sunitinib) * More than two prior systemic non-platinum cytotoxic chemotherapy regimens * Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to other medications administered \>30 days prior to study enrollment * History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis * Uncontrolled and/or intercurrent illness * Patients who are pregnant or breastfeeding * Known human immunodeficiency virus (HIV)